From the Centers for Disease Control. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus.
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000328:Adult; D000336:Aerosols; D000900:Anti-Bacterial Agents; D002648:Child; D004338:Drug Combinations / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007223:Infant; D007958:Leukocyte Count; D008297:Male; D010419:Pentamidine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control*; D011247:Pregnancy; D012008:Recurrence; D012307:Risk Factors; D013420:Sulfamethoxazole / Q000009:adverse effects / Q000627:therapeutic use; D006377:T-Lymphocytes, Helper-Inducer; D014295:Trimethoprim / Q000009:adverse effects / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D015215:Zidovudine / Q000627:therapeutic use
D000336:Aerosols; D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D015215:Zidovudine; D010419:Pentamidine; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole